Liver injury caused by oral anticoagulants: A population-based retrospective cohort study.
Helgi K BjörnssonDavid O GudmundssonEinar Stefan BjörnssonPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
Rivaroxaban was the only OAC associated with DILI during the 10-year study period. Approximately 1 in 1100 patients treated with rivaroxaban developed DILI. Other OACs were not associated with liver injury in this population-based study.